:

Takuya Mikoshiba1, Mariko Sekimizu2, Takeyuki Kono2

  • 1Department of Otolaryngology, Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan. t-mikoshiba@keio.jp.

Endocrine
|June 28, 2025
PubMed
概括

伦瓦提尼布在治疗无塑性甲状腺癌 (ATC) 方面表现出适度的疗效. 用降低剂量开始治疗可能会改善治疗效益和生存结果,对于无法耐受标准24毫克每日剂量的患者.